



RECEIVED

JAN 15 2003

PATENT

#7

Practitioner's Docket No. MPI98-048CP1CN1M

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Andrew D.J. Goodearl and Maria A. Glucksmann
Application No.: 09/911,667 Group No.: 1655
Filed: July 24, 2001 Examiner: N/A
For: OCTLP, A PROTEIN HAVING HOMOLOGY TO THE ORGANIC AND SUGAR
TRANSPORTER FAMILY OF PROTEINS, AND USES THEREOF

Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT

The information disclosure statement submitted herewith is being filed:

☒ Within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).

OR

[] *After* three months of the filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but *before* the mailing date of either:

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

☒ deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

☒ with sufficient postage as first class mail.

☐ as "Express Mail Post Office to Address"
Mailing Label No.

TRANSMISSION

☐ transmitted by facsimile to the Patent and Trademark Office.

Signature

Sean Hunziker

(type or print name of person certifying)

Date: January 9, 2003

***WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 3)

Practitioner's Docket No. MPI98-048CP1CN1M

- (1) a final action under Section 1.113,
- (2) a notice of allowance under Section 1.311, or
- (3) an action that otherwise closes prosecution in the application

whichever occurs first.

☐ Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00).

☐ Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1).

☐ No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2).

FEE PAYMENT

3. ☐ The fee due is set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c) (\$180.00).

☒ Applicant believes no fee is due in connection with this submission.

Fee due \$0.00

METHOD OF PAYMENT OF FEE

4. ☐ Attached is a check in the amount of \$ _____ .
- ☐ Charge Account No. 501668 in the amount of \$0.00 .
- ☐ A duplicate of this request is attached.

☒ If any additional fees are due, please charge Account 501668.

January 9, 2003

MILLENNIUM PHARMACEUTICALS, INC.

By Tracy M. Sioussat

Tracy M. Sioussat
Attorney/Agent for Applicant
Registration No. 50,609
75 Sidney Street
Cambridge, MA 02139
Telephone - 617-374-7679
Facsimile - 617-551-8820



Practitioner's Docket No. MPI98-048CP1CN1M

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Andrew D.J. Goodearl and Maria A. Glucksmann
Application No.: 09/911,667 Group No.: 1655
Filed: July 24, 2001 Examiner: N/A
For: OCTLP, A PROTEIN HAVING HOMOLOGY TO THE ORGANIC AND SUGAR
TRANSPORTER FAMILY OF PROTEINS, AND USES THEREOF

Commissioner for Patents
Washington, D.C. 20231

RECEIVED
JAN 15 2003
TECH CENTER 1600/2000

INFORMATION DISCLOSURE STATEMENT

List of Sections Forming Part of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

1. ☒ Preliminary Statements
2. ☒ Forms PTO/SB/08A and 08B (substitute for Form PTO-1449)
3. ☒ Identification of Prior Application in Which Listed Information Was Already Cited and for Which No Copies Are Submitted or Need Be Submitted (AM through BF)
4. ☒ Copy of CA Accompanying This Statement

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*


- ☒ with sufficient postage as first class mail. ☐ as "Express Mail Post Office to Address" Mailing Label No.

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Signature

Date: January 9, 2003


Sean Hunziker
(type or print name of person certifying)

***WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Preliminary statements

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

**Identification of Prior Application in Which Listed Information Was Already Cited
and for Which No Copies Are Submitted or Need Be Submitted**

This application relies, under 35 U.S.C. section 120, on the earlier filing date of prior application Serial No. 09/342,959, filed on June 29, 1999.

The cited references were submitted to, and/or cited by, the Office in the prior application(s) and, therefore, are not required to be provided in this application. However, the undersigned will provide additional copies upon request. Please note that due to duplication of the AQ identifier, the Lernal et al. previously submitted reference has been given the new identifier of AR.

Copies of Listed Information Items Accompanying This Statement

Legible copies of all items listed in Forms PTO/SB/08A and 08B (substitute for Form PTO-1449) accompany this information statement.


- [x] Exceptions to above
[x] Items in prior application, from which an earlier filing date is
claimed for this application, as identified above

Respectfully submitted,

MILLENNIUM PHARMACEUTICALS, INC.

January 9, 2003

By:



Tracy M. Sioussat
Attorney/Agent for Applicant
Registration No. 50,609
75 Sidney Street
Cambridge, MA 02139
Telephone - 617-374-7679
Facsimile - 617-551-8820

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known**Application Number**

09/911,667

Filing Date

July 24, 2001

First Named Inventor

Andrew D.J. Goodearl and Maria A. Glucksmann

Group Art Unit

1655

Examiner Name

N/A

Attorney Docket Number

MPI98-048CP1CN1M

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]


Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁸Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



Please type a plus sign (+) inside this box → ☐ +

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0654-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	09/911,667		
		Filing Date	July 24, 2001		
		First Named Inventor	Andrew D.J. Goodearl and Mark A. Glucksmann		
		Group Art Unit	1655		
		Examiner Name	N/A		
Sheet	1	of	2	Attorney Docket Number	MPI98-048CP1CN1M

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²
	AM	Grundemann et al., "Drug Excretion Mediated By a New Prototype of Polyspecific Transporter" Nature, 372:549-552, 1994	
	AN	Roger Janz et al., "SVOP, An Evolutionary Conserved Synaptic Vesicle Protein Suggests Novel Transport Functions of Synaptic Vesicles", Journal of Neuroscience, 18(22):9269-9281, November 15, 1998	
	AO	Lopez-Nieto et al., "Molecular Cloning and Characterization of NKT, A Gene Product Related to the Organic Cation Transporter Family..." Journal of Biological Chemistry, 272(10): 6471-6478, 1997	
	AP	Okuda et al., "cDNA Cloning and Functional Expression of a Novel Rat Kidney Organic Cation Transporter, OCT2", Biochemical & Biophysical Research Communications, 224:500-507, 1996	
	AQ	Simonson et al., "Molecular Cloning and Characterization of a Novel Liver-Specific Transport Protein", Journal of Cell Science, 107:1065-1072, 1994	
	AR	Lerner et al., "Isolation of a Novel Gene Underlying Batten Disease, CLN3," Cell, 82: 949-957, 1995	
	BA	M. D. Adams et al "dbEST Id: 991309," April 21, 1997 (sequence) GenBank (online). Bethesda, MD, USA: National Center for Biotechnology Information (Retrieved on September 20, 2000), Retrieved from the Internet URL: http://www.ncbi.nlm.nih.gov/ , Accession No. AA349847	
	BB	M. D. Adams et al "dbEST Id: 27325," August 3, 1993, GenBank (online). Bethesda, MD, USA: National Center for Biotechnology Information, (Retrieved on September 20, 2000), Retrieved from the Internet URL: http://www.ncbi.nlm.nih.gov/ , Accession No. T08271	
	BC	M. D. Adams et al "dbEST Id: 991853," April 21, 1997, GenBank (online). Bethesda, MD, USA: National Center for Biotechnology Information, (Retrieved on September 20, 2000), Retrieved from the Internet URL: http://www.ncbi.nlm.nih.gov/ , Accession No. AA350545	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here is English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.


Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Complete if Known

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	09/911,667
Filing Date	July 24, 2001
First Named Inventor	Andrew D.J. Goodearl and Maria A. Glucksmann
Group Art Unit	1655
Examiner Name	
Attorney Docket Number	MPI98-048CP1CN1M

Sheet 2 of 2

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²
	BD	Adams, M.D. et al, "dbEST Id: 993001," April 21, 1997, (sequence) GenBank (online). Bethesda, MD, USA: National Center for Biotechnology Information (Retrieved on September 20, 2000), Retrieved from the Internet URL: http://www.ncbi.nlm.nih.gov/ , Accession No. AA351693	
	BE	Auffray, C. et al, "dbEST Id: 129165," February 22, 1995, (sequence) GenBank (online). Bethesda, MD, USA: National Center for Biotechnology Information (Retrieved on September 20, 2000), Retrieved from the Internet URL: http://www.ncbi.nlm.nih.gov/ , Accession No. F08438	
	BF	Janz, R. et al. "Rattus Norvegicus SV2 Related Protein (SVOP) mRNA, Complete cds," November 21, 1998, (sequence) GenBank (online). Bethesda, MD, USA: National Center for Biotechnology Information (Retrieved on September 20, 2000), Retrieved from the Internet URL: http://www.ncbi.nlm.nih.gov/ , Accession No. AF060173	

RECEIVED
JAN 15 2003
TECH CENTER 1600/2900

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.